Affymax

Affymax FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Affymax (AFFY) as of Oct 9, 2026 is 466.85 %.

FCF Conversion

466.85 %

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Affymax is 2013 466.85 % . FCF Conversion Rate (FCF/EBITDA) of Affymax was 2012 - . It decreases by % lower compared to the previous year.

The Affymax FCF Conversion history

The Affymax FCF Conversion history
YEARFCF ConversionYoY
466.85 %—
Access this data via the Eulerpool API

Affymax Stock analysis

What does Affymax do? Affymax Inc is a leading biotechnology company specializing in the development of innovative therapeutics for patients with serious diseases. The company was founded in 2001 and is headquartered in Palo Alto, California. Affymax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Affymax stock

FCF Conversion Rate (FCF/EBITDA) of Affymax is 466.85 % in 2013.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Affymax since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Affymax with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Affymax

All Key Metrics — Affymax